Teligent, Inc, a specialty generic pharmaceutical company, develops, manufactures, markets, and sells generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. It offers generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms. The company is also involved in contract manufacturing and development business, including the development, manufacturing, filling, and package of topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as for over-the-counter and cosmetic markets.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone856-697-1441
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$65.86 million
Profitability
Miscellaneous
Employees189
Next Earnings Date8/14/2019 (Estimated)
OptionableOptionable
Teligent (NASDAQ:TLGT) Frequently Asked Questions
What is Teligent's stock symbol?
Teligent trades on the NASDAQ under the ticker symbol "TLGT."
How were Teligent's earnings last quarter?
Teligent Inc (NASDAQ:TLGT) posted its quarterly earnings data on Monday, May, 6th. The company reported ($0.10) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.08) by $0.02. The firm had revenue of $13.12 million for the quarter, compared to analysts' expectations of $16.60 million. Teligent had a negative return on equity of 103.41% and a negative net margin of 73.56%. View Teligent's Earnings History.
When is Teligent's next earnings date?
What price target have analysts set for TLGT?
2 brokers have issued 12 month target prices for Teligent's stock. Their predictions range from $3.00 to $3.00. On average, they anticipate Teligent's stock price to reach $3.00 in the next year. This suggests a possible upside of 597.7% from the stock's current price. View Analyst Price Targets for Teligent.
What is the consensus analysts' recommendation for Teligent?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teligent in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Teligent.
Has Teligent been receiving favorable news coverage?
Media stories about TLGT stock have trended somewhat positive recently, InfoTrie Sentiment reports. The research group scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Teligent earned a coverage optimism score of 1.4 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Teligent.
Who are some of Teligent's key competitors?
Some companies that are related to Teligent include Humanigen (HGEN), Paratek Pharmaceuticals (PRTK), Tyme Technologies (TYME), AVEO Pharmaceuticals (AVEO), AgeX Therapeutics (AGE), Fortress Biotech (FBIO), Tiziana Life Sciences (TLSA), Imprimis Pharmaceuticals (IMMY), Aquestive Therapeutics (AQST), ASLAN PHARMACEU/ADR (ASLN), Verastem (VSTM), Chembio Diagnostics (CEMI), Avadel Pharmaceuticals (AVDL), Corvus Pharmaceuticals (CRVS) and Trevena (TRVN).
What other stocks do shareholders of Teligent own?
Who are Teligent's key executives?
Teligent's management team includes the folowing people:
- Mr. Jason Grenfell-Gardner M.B.A., M.B.A, Pres, CEO & Director (Age 44)
- Mr. Stephen Richardson, Chief Scientific Officer (Age 53)
- Mr. Martin Wilson, Gen. Counsel (Age 42)
- Mr. Damian Finio, Corp. Sec. & CFO (Age 49)
- Ms. Nadya Lawrence, Sr. VP of Technical Services (Age 50)
Who are Teligent's major shareholders?
Teligent's stock is owned by many different of retail and institutional investors. Top institutional shareholders include AMI Asset Management Corp (5.07%), Sanders Morris Harris LLC (3.90%), Spark Investment Management LLC (0.42%), Private Advisors LLC (0.32%) and Private Advisors LLC (0.32%). Company insiders that own Teligent stock include Bhaskar Chaudhuri, Carole Ben-Maimon, Damian Finio, James C Gale, Jason Grenfell-Gardner, Jenniffer Collins, Stephen Richardson and Steven H Koehler. View Institutional Ownership Trends for Teligent.
Which major investors are selling Teligent stock?
Which major investors are buying Teligent stock?
TLGT stock was purchased by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC, Spark Investment Management LLC and AMI Asset Management Corp. Company insiders that have bought Teligent stock in the last two years include Bhaskar Chaudhuri, Carole Ben-Maimon, Damian Finio, James C Gale, Jason Grenfell-Gardner, Jenniffer Collins, Stephen Richardson and Steven H Koehler. View Insider Buying and Selling for Teligent.
How do I buy shares of Teligent?
Shares of TLGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Teligent's stock price today?
One share of TLGT stock can currently be purchased for approximately $0.43.
How big of a company is Teligent?
Teligent has a market capitalization of $23.16 million and generates $65.86 million in revenue each year. The company earns $-36,260,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis. Teligent employs 189 workers across the globe.View Additional Information About Teligent.
What is Teligent's official website?
How can I contact Teligent?
Teligent's mailing address is 105 LINCOLN AVENUE, BUENA NJ, 08310. The company can be reached via phone at 856-697-1441 or via email at [email protected]
MarketBeat Community Rating for Teligent (NASDAQ TLGT)
MarketBeat's community ratings are surveys of what our community members think about Teligent and other stocks. Vote "Outperform" if you believe TLGT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TLGT will underperform the S&P 500 over the long term. You may vote once every thirty days.
